Search filters
Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 373
  • 1196
  • 568
  • 28
  • 44
  • 2
  • 1128
  • 1197
  • 5

Found 1202 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

EndurAnt Stent Graft system vs ExcluDer endoprothesis: a global prospectiVe rANdomized Clinical trial in sac rEgression (ADVANCE Study)

99 years or below
All genders
This post-market, prospective, interventional, global, multi-center, randomized, nonblinded, dual-arm, clinical trial study will generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft System versus Gore Excluder/Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysm (AAA). The primary objective is to evaluate sac regression outcomes in …
Learn More

Immune Impact of Bevacizumab in Patients with Recurrent Glioblastoma

99 years or below
All genders
PURPOSE/DESCRIPTION: Primary: to perform high-dimensional flow cytometry on peripheral blood of patients with recurrent glioblastoma receiving standard of care anti-VEGF therapy with bevacizumab to understand the immune impact of the drug on various immune cell populations. Secondary: To perform an evaluation of ex vivo cytokine production in peripheral blood T …
Learn More

Phase 3b Open-Label Multicenter Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies 221AD103 221AD301 221AD302 and 221AD205

99 years or below
All genders
This open-label, single arm clinical study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer's disease who were actively participating in Aducanumab clinical studies 103, 205, 301, or 302 (aducanumab feeder studies) as of March 21st 2019. Participants who participated in 221AD302 will …
Learn More

UPCC 11222: A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies

99 years or below
All genders
The purpose of this study is to test the safety and effectiveness of domvanalimab when given together with zimberelimab with and without chemotherapy. We would like to rely on WCG the IRB of record for this study.
Learn More

UPCC 02120: PrE0113: A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

99 years or below
All genders
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized …
Learn More

Analysis of lymphatic fluid from the thoracic duct of healthy subjects and patients with MS before and during Ofatumumab treatment

99 years or below
All genders
The overall objectives of this study are to evaluate feasibility and safety of thoracic duct sampling, including "in-and-out" cannulation and "indwelling" catheterization in early MS and to compare cellular and signaling markers in thoracic duct lymph compared to measures in the blood, within and across populations of MS patients before …
Learn More

A Phase 3 Double-Blind Randomized Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) AG348-C-018

99 years or below
All genders
Phase 3
To compare the effect of mitapivat versus placebo on transfusion burden in subjects with alpha- or beta-transfusiondependent thalassemia (TDT) Transfusion reduction response (TRR), defined as a 50% reduction in transfused red blood cell (RBC) units with a reduction of greater that or equal to 2 units of transfused RBCs in …
Learn More

I5T-MC-AACI Assessment of Safety Tolerability and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease Phase II

99 years or below
All genders
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
Learn More

Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients

99 years or below
All genders
Phase 2
Primary Objectives Cohort 1: To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when administered with cemiplimab among recurrent malignant glioma participants. Cohort 2: To determine if neoadjuvant immune checkpoint blockade (ICB) with ASP8374, cemiplimab and the combination of ASP8374 plus cemiplimab will induce …
Learn More

A Randomized Controlled Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly

99 years or below
All genders
Phase 3
1) To evaluate the effect of paltusotine versus placebo on IGF-1(Insulin-like growth factor) response 2) To evaluate the effect of paltusotine versus placebo on IGF-1 level 3) To evaluate the effect of paltusotine versus placebo on GH (growth hormone) response 4) To evaluate the effect of paltusotine versus placebo on …
Learn More
511 - 520 of 1202